Sutro Biopharma

Sutro Biopharma is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Its key product candidate is luveltamab tazevibulin (luvelta), a folate receptor alpha (FolRα)-targeting ADC. Luvelta utilizes Sutro's proprietary cell-free XpressCF platform to enable site-specific conjugation and incorporation of both a cytotoxin and immunostimulatory component.

Luvelta is currently being evaluated in multiple clinical trials for the treatment of ovarian, endometrial, lung, and rare pediatric cancers that express FolRα. In January 2024, compelling anti-leukemic activity was demonstrated with luvelta in relapsed/refractory pediatric patients with CBF/GLIS acute myeloid leukemia (AML). Part two of the REFR⍺ME-O1 registrational trial for platinum-resistant ovarian cancer is now enrolling patients. Additional trials are planned to begin in 2024, including a Phase 2 study in non-small cell lung cancer and a registration-enabling pediatric CBF/GLIS AML study (REFR⍺ME-P1).

Sutro is utilizing its cell-free XpressCF and other proprietary technologies to build a pipeline of next-generation ADCs and biotherapeutics across multiple disease areas. The company has active collaborations with partners like Astellas, Merck, BMS, and Vaxcyte, generating over USD 854 million in payments through 2023.

Key customers and partnerships

In June 2022, Sutro entered into a worldwide strategic collaboration and licensing agreement with Astellas focused on the discovery and development of novel immunostimulatory ADCs (iADCs) enabled by Sutro's technology. The deal included USD 90 million upfront, up to USD 422.5 million in potential milestones per product candidate, and royalties.

Sutro is also collaborating with Merck on MK-1484, a biologic in clinical trials as a monotherapy and in combination with pembrolizumab for solid tumors. With Bristol Myers Squibb, Sutro is developing CC-99712, a BCMA-targeting ADC in trials for multiple myeloma.